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Somatic loss of heterozygosity (LOH) has been widely reported in breast cancer as a means of identifying putative
tumor-suppressor genes. However, individual studies have rarely spanned more than a single chromosome, and the
varying criteria used to declare LOH complicate efforts to formally differentiate regions of consistent versus sporadic
(random) loss. We report here the compilation of an extensive database from 151 published LOH studies of breast
cancer, with summary data from 115,000 tumors and primary allelotypes from 14,300 tumors. Allelic loss was
evaluated at 1,168 marker loci, with large variation in the density of informative observations across the genome.
Using studies in which primary allelotype information was available, we employed a likelihood-based approach
with a formal chromosomal instability and selection model. The approach seeks direct evidence for preferential
loss at each locus compared with nearby loci, accounts for heterogeneity across studies, and enables the direct
comparison of candidate regions across the genome. Striking preferential loss was observed (in descending order
of significance) in specific regions of chromosomes 7q, 16q, 13q, 17p, 8p, 21q, 3p, 18q, 2q, and 19p, as well as
other regions, in many cases coinciding with previously identified candidate genes or known fragile sites. Many of
these observations were not possible from any single LOH study, and our results suggest that many previously
reported LOH results are not systematic or reproducible. Our approach provides a comparative framework for
further investigation of regions exhibiting LOH and identifies broad genomic regions for which there exist few
data.
Introduction
Breast cancer is among the most common incident can-
cers in the world (Parkin et al. 2001) and causes nearly
200,000 invasive cases and 40,000 deaths each year in
the United States (American Cancer Society 2002). A
number of inherited cancer syndromes have been iden-
tified that confer elevated breast cancer risk (Couch and
Weber 1997), and two common highly penetrant dom-
inant disease genes have been identified (Ellisen and Ha-
ber 1998; Buchholz et al. 1999). However, inherited sus-
ceptibility appears to account for a minority of cases
(Couch and Weber 1997), and, in general, breast cancer
is thought to be a complex, multifactorial disease re-
sulting from an accumulation of multiple genetic alter-
ations (Nathanson et al. 2001).
Loss of heterozygosity (LOH), the loss of a normal,
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functional allele at a heterozygous locus, is the most com-
mon type of somatic alteration found in primary human
breast tumors (Callahan et al. 1993). Through testing of
tumor and normal reference DNA at a series of poly-
morphic marker loci, numerous allelic analyses of breast
cancer have demonstrated frequent LOH on chromo-
some arms 1p, 1q, 3p, 6q, 7q, 8p, 11p, 13q, 16q, 17p,
17q, 18q, and 22q (Lasko et al. 1991; Devilee and Cor-
nelisse 1994; Callahan 1998). As articulated by Lasko et
al. (1991) and mathematically formalized by Newton and
colleagues (Newton et al. 1998; Newton and Lee 2000),
consistent LOH in a genomic region implicates the pres-
ence of tumor-suppressor genes (TSGs) or other genes
related to tumor pathogenesis. For ease of discussion, we
will refer to a region of true excess loss as evidence for
a TSG, although establishing causality must await further
functional validation.
Despite the hundreds of LOH studies of breast cancer,
the number and identity of TSGs relevant to this disease
remain largely unknown (Devilee et al. 2001), with most
studies examining a single genomic region with limited
resolution. The literature lacks a standard nomencla-
ture, with various terms (e.g., “allelic imbalance,” “al-
lelic loss,” and “LOH”) used essentially equivalently.
Miller et al.: Pooled Analysis of LOH in Breast Cancer 749
The analysis of such data is further complicated by the
widely varying criteria used to declare LOH. For ex-
ample, in electrophoretic allele typing, a decrease in al-
lele intensity of at least 50% in tumor versus normal
DNA has been used (Gaki et al. 2000), as has a differ-
ence in the allele intensity ratio of 20% (Kollias et al.
2000). Such quantitative distinctions belie the certainty
with which LOH is often described. In addition, most
LOH studies of breast cancer provide limited or no spec-
ification of tumor stage or histology, presenting an ad-
ditional challenge in comparing across studies. For all
of these reasons, previous summaries of LOH in breast
cancer have been largely qualitative, consisting of de-
scriptions of chromosomal arms or regions reported
frequently lost (Lasko et al. 1991; Couch and Weber
1997). The resolution of these summaries typically is
low, and it is not obvious how to carefully rank the
evidence in different chromosomal regions. Further-
more, without a framework for carefully comparing de-
letion rates, such descriptions may be prone to publi-
cation bias. As we demonstrate below, the extent of the
published LOH literature varies widely by chromosome,
and regions containing known or suspected TSGs (e.g.,
BRCA1 [MIM 113705]) have been studied most exten-
sively. Of particular concern are studies examining in-
dividual candidate genes—elevated LOH does not nec-
essarily implicate a gene, since interstitial deletions
containing a TSG can create a “bystander effect” of
elevated LOH in broad regions. Such methodological
difficulties have led some investigators to question the
very foundations of LOH analysis (Tomlinson et al.
2002).
Other problems with traditional LOH analysis may
be viewed as statistical, resulting from informal or
overly optimistic interpretations of data that may oth-
erwise be sound. In individual LOH studies, distinct
regions of elevated loss are often reported without con-
sidering the effects of chance variation. For example,
Kerangueven et al. (1997) reported five regions of LOH
on chromosome 17, with an average of 30 informative
samples and LOH proportions ranging from 0.23 to
0.47. Noviello et al. (1996) described four distinct
regions of increased allelic loss on chromosome 6q, with
LOH proportions in these regions ranging from 0.21 to
0.39 for most of the average 46 informative samples.
Such variation cannot be distinguished from random
binomial variation accompanying sporadic, nonspecific
loss. As we shall see from the present data set (see the
“Results” section), several chromosome arms show av-
erage loss proportions 10.30 without any clearly defined
subregion of excess loss. Moreover, localization of
regions of elevated LOH is usually performed infor-
mally, with qualitative descriptions of smallest com-
monly deleted regions or minimal overlapping loss (Na-
gai et al. 1995; Bieche et al. 1999). Such localization
methods can be very misleading, since the occurrence
of multiple TSGs or sporadic deletions in a broader
region of elevated LOH can result in incorrect or op-
timistically narrow regions (Devilee et al. 2001).
A Model for Allelic Loss
Newton and colleagues (Newton et al. 1998; Newton
and Lee 2000) have used a parametric “instability-se-
lection” model to describe LOH data. The model as-
sumes that loss (instability) is determined by a binary
Markov process in precancerous tissue, followed by
preferential tumor growth (selection of a cell lineage to
become a clinically detectable tumor) if a lost segment
contains a TSG. The presumed genetic mechanism in-
volves LOH as either the first inactivating event in Knud-
son’s two-hit model (followed by mutation, methylation,
or other inactivation of the remaining wild-type allele
in the lineage) or as the second event, causing the re-
moval of the remaining wild-type allele after one allele
has been inactivated (Devilee et al. 2001). Other LOH
mechanisms have been described (Newsham et al. 1997),
and the likely sequence of LOH/mutation events remains
controversial (Wilentz et al. 2001). Indeed, a second
event may be unnecessary for TSGs exhibiting haploin-
sufficiency (Kwabi-Addo et al. 2001). Nonetheless, it is
widely presumed that regions of consistently high LOH
are functionally important in tumorigenesis. The New-
ton model can be used to test for the presence of a TSG
via a likelihood ratio and resulting LOD score, in a man-
ner similar to linkage analysis. The approach is attractive
because it provides an explicit framework for testing and
inference. The model also clarifies that the hallmark of
a TSG should be preferential loss in a region of a chro-
mosome, compared with sporadic loss at other regions.
To fully exploit the marker-to-marker correlation in
LOH, the method requires use of the primary “allelo-
type” data (i.e., the loss/retention data for each locus
and each tumor) rather than averaged summaries across
the tumors. Such primary data is often not reported in
studies of LOH or is reported incompletely (sometimes
only for those samples showing the greatest average
loss). A high proportion (∼50%) of genotyped LOH data
may also be missing because of constitutive homozygous
genotypes or impaired sample quality of resected tissue.
Furthermore, combining evidence from multiple studies
is complicated by biological and technical heterogeneity.
The Challenge
An illustration of the difficulties in analyzing such data
is given in figure 1, which shows the proportion of LOH
(among informative marker observations) for each of 47
studies on chromosome 17. The variation in loss rates
across the studies and the incomplete chromosomal cov-
erage of any one study presents an evident challenge in
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Figure 1 LOH on chromosome 17 (47 studies). Each point rep-
resents the proportion LOH observed at a marker within a single study.
Observations within the same study are connected by lines, with widths
proportional to the average number of informative observations per
marker for that study. A smoothed density plot of informative obser-
vations (above the scatterplot) shows that the data are concentrated
at 17pter and the regions containing TP53 and BRCA1. Similar scat-
terplots for all chromosomes and accompanying citations are available
as supplemental data.
identifying regions of consistent and significant loss. For
example, by examining a small interval, we can test
whether the average loss rate appears to vary among
studies. A simple goodness-of-fit test (Ott et al. 2000)
for average loss proportions in the region 60–80 cM
(heavily studied because it contains BRCA1) reveals sig-
nificant heterogeneity across studies that have markers
in the interval ( ; ). In regions2x p 158.6 P K .0000134
covered by few studies, such heterogeneity is especially
problematic, since it confounds any attempt to attribute
an apparently high loss rate to the loss of a TSG. Al-
though a gradient is apparent in figure 1, with 17pter
showing higher average loss than 17qter, further con-
clusions are difficult to draw from casual inspection.
To provide a comprehensive view of LOH in breast
cancer and to evaluate the model-based evidence for
TSGs, we set out to identify all such studies that reported
at least portions of the data as allelotypes. At the time
the data were gathered (in late 2001), a total of 151
studies were identified that met this inclusion criterion,
published from 1989 to June of 2001. The interval spans
technological improvements in marker genotyping from
RFLPs to modern microsatellites and SNPs. The various
terms used to describe allelic loss were standardized, and
the data were manually recorded. The summary evidence
based on average loss proportions was used to provide
a rough description of LOH across the genome. We then
applied a likelihood-ratio approach to the allelotype
data, accounting for heterogeneity by adopting study-
specific parameters. The resulting pooled analysis (sim-
ilar to a meta-analysis, but using published data rather
than summary statistics) highlights several small regions
of striking preferential loss on the genome, while finding
little evidence in other widely studied regions.
Material and Methods
Primary and Summary Data
Articles describing LOH in breast cancer were iden-
tified in Medline searches. The following search key-
words were used: “chromosome deletion OR hetero-
zygote OR allel$2 loss$2 OR deletion map$4 OR LOH
OR loss of heterozygosity OR microsatellite repeat$”
AND “breast neoplasms OR breast.” Here, “$” repre-
sented a wildcard in then-current Medline syntax. This
search strategy initially yielded 1,178 articles. The ab-
stracts of the resulting matches were used to identify a
smaller number of articles likely to contain allelotype
data, and review of these articles identified 151 studies
meeting the inclusion criteria, representing ∼15,000 tu-
mors. Only 19 of the studies spanned more than one
chromosome. Table 1 summarizes the coverage of the
genome and tumor samples studied; 52.3% of the studies
(and 64.8% of the individual samples) contained no de-
scriptions of tumor histology, and, among those samples
with sufficient descriptions, the most common classifi-
cations were invasive ductal carcinoma (80.0%), inva-
sive lobular carcinoma (7.8%), and (noninvasive) ductal
carcinoma in situ (DCIS; 6.7%). Tumor histology was
generally unavailable for individual samples within the
allelotypes and thus could not be used for stratification
or careful subgroup analysis. The six articles with 120%
noninvasive carcinomas (DCIS) were analyzed sepa-
rately, and all but two of the remaining articles reported
!10% noninvasive cancers. The inclusion criteria fa-
vored studies of primary tumor samples, although one
cell-line study met the criteria (Bieche et al. 1998). Ex-
clusion of this study has essentially no effect on the re-
sults below. Detailed descriptions of the 151 studies are
provided in table C1 of appendix C (online only) and
on the authors’ Web site; all the primary data compiled
from these studies are also available on the authors’ Web
site. Several of the studies covered a chromosome with
only a single marker, and for these the likelihood could
not be calculated. Still others covered multiple chro-
mosomes, so that the total number of informative chro-
mosome studies was 164 for the invasive studies and 8
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Table 1
Summary of LOH Articles Compiled in the Database
CHROMOSOME
NO. OF
Individual
Studies
Unique
Markers
Tumor Samples
(Allelotypes)
Informative
Observations
(Allelotype
Observations)
per Mb
1 21 133 1,268 (455) 24.3 (15.0)
2 9 23 179 (94) 3.3 (1.3)
3 15 70 853 (192) 19.3 (6.2)
4 5 24 56 (70) 3.2 (5.2)
5 5 22 34 (31) .9 (.5)
6 13 92 1,164 (294) 26.7 (15.4)
7 12 70 717 (133) 39.1 (7.8)
8 17 85 957 (401) 48.5 (23.8)
9 11 55 579 (274) 27.3 (10.1)
10 11 41 330 (142) 9.3 (3.6)
11 27 100 3,156 (736) 74.7 (24.6)
12 4 10 19 (33) .7 (.5)
13 18 41 1,653 (346) 34.4 (18.7)
14 4 6 88 (76) 2.3 (1.7)
15 3 2 12 (0) .4 (.0)
16 22 106 1,851 (480) 70.8 (37.5)
17 47 150 4,966 (1,249) 212.4 (65.2)
18 9 43 767 (204) 54.0 (13.2)
19 5 9 75 (51) 3.1 (1.2)
20 4 4 18 (26) 1.2 (.2)
21 4 13 154 (18) 22.3 (2.9)
22 7 41 238 (72) 3.4 (19.0)
X 3 33 80 (40) 4.3 (4.2)
Total 151a 1,173 15,417a (4,365a) 26.8 (10.9)
NOTE.—A detailed record of the 151 individual studies used in the pooled analysis
is included in appendix C (online only).
a Total adjusted so that studies testing a panel of tumors across more than one
chromosome were counted only once.
for the noninvasive studies. There was considerable var-
iation in the number of informative observations across
the chromosomes (table 1) and across studies.
Newton and Lee (2000) described genomic positions
rescaled as equally spaced on the unit interval, while less
formal LOH mapping efforts have often used the sex-
averaged meiotic genetic map. The markers in our present
studies were initially placed according to the Location
Database (LDB) (2000 and 2001 builds; Genetic Epide-
miology Group Web site) (Collins et al. 1996). Each locus
in the LDB is assigned a composite genetic location based
on available genetic and radiation hybrid data, and our
likelihood computation based on the assignments ap-
peared to be successful. It was recognized, however, that
the draft assembly of the human genome had reached
sufficient quality that we could use it to determine the
physical position of the loci, thus greatly improving our
ability to integrate maps and identify candidate tumor
suppressors. A total of 1,168 unique markers were used
in the studies, and, of these, 863 (73.9%) could be
uniquely placed on the December 22, 2001 National Cen-
ter for Biotechnology Information assembly (the most cur-
rent when this step was performed). For the placement,
we used a combination of STS placements from J. Kent
(UCSC Genome Bioinformatics Home Page) and direct e-
PCR mapping (Schuler 1997). The remaining 305 mark-
ers were mostly RFLPs without sufficient sequence infor-
mation for direct genome placement, and for these we
used the LDB. Approximate physical positions for the 305
markers were predicted by third-degree polynomial re-
gression fits to the physical versus genetic location for
each chromosome, through use of nearly 800 markers
that could be placed on the draft assembly and also ap-
peared in the LDB.
The primary allelotype data was recorded for each
study, representing 14,300 tumor samples. Five cate-
gories were used to classify the allelic status at each
marker. Table A (online only) outlines the system of clas-
sification. Most studies also reported overall allelic loss
(per informative observation) for all of the markers.
These data are distinct from summaries based on the
reported allelotypes, since many studies report average
752 Am. J. Hum. Genet. 73:748–767, 2003
loss for all tumor samples but report allelotypes for only
a portion of the tumors (hence, 15,000 tumors but only
4,300 allelotypes). Both the summaries and allelotypes
are available as supplementary material on the authors’
Web site.
Allelotype data on homozygous deletions or markers
with allelic gain (amplification) was not extensive
enough to enable refined analysis of these categories. In
the analyses that follow, the data was further grouped
into three categories: “lost” (loss of heterozygosity or
homozygous deletion), “retained” (retention of hetero-
zygosity or allelic gain), or “missing” (missing/not in-
formative/not typed). Any observation that was not
missing was considered informative, and informative ob-
servations comprised 56.0% of the allelotype data. Only
a few studies reported data across multiple chromo-
somes; to avoid excessive complication, we treated the
data from each study on each chromosome indepen-
dently. One study (Kollias et al. 2000) involved bilateral
tumors, which were treated as independent observations.
The Likelihood Approach
The instability-selection model (Newton et al. 1998)
supposes that breakpoints and loss occur on the chro-
mosome, prior to clonal tumor growth, according to a
random Markov process with specified transition rates
between the states of “loss” and “no loss.” This as-
sumption is similar to breakpoint assumptions used in
linkage mapping (Ott 1999) and radiation hybrid map-
ping (Lange et al. 1995). If a lost segment includes a
TSG, then the loss provides a selective growth advantage
to the clonal population compared with the surrounding
tissue. Together, these assumptions accord with our un-
derstanding of tumor growth resulting from loss of sup-
pression (Lasko et al. 1991).
The application of this approach requires allelotype
data. We provide here a basic description of the model
and likelihood; detailed expositions are provided else-
where (Newton et al. 1998; Newton and Lee 2000). A
full specification of the model involves nonidentifiable pa-
rameters, including growth rates for tissue before and
after loss of suppression. However, on the basis of the
observable data, the likelihood for a single LOH study
can be expressed in terms of four parameters: x*, the
location of the TSG; d, the background random loss rate
of chromosomal segments; q, the loss rate at the TSG;
and l, the breakpoint rate parameter prior to selection.
The background loss d is the loss rate prior to selection,
due to differential growth of the clonal population; after
selection, it is an asymptotic rate for genomic positions
infinitely distant from the TSG. Under the null hypothesis,
no tumor suppressor exists—that is, . Under theqp d
alternative hypothesis, . We provide the form of theq 1 d
likelihood in appendix A. Although the model simplifies
complex biological processes (Devilee et al. 2001), it is a
parsimonious model that captures essential features of the
data, including inherent randomness of outcomes, loss
rates that vary by genomic position, and positive corre-
lation of loss events among nearby markers. Observations
on the X chromosome were treated in the same manner
as the autosomes, although, because of X inactivation in
females (Strachan and Read 1999) (and therefore no sec-
ond “hit” required), any observed excess loss would re-
quire careful biological interpretation.
The Profile LOD
We extend the instability-selection model in a manner
appropriate to multiple studies, only some of which may
show evidence for a TSG. For a single study i, we denote
the set of allelotypes as datai and similarly use subscripts
for the parameters di, qi, and li. The use of such study-
specific parameters accounts for heterogeneity that may
arise from a variety of biological and technical sources.
In contrast, x* is considered a fixed property of the TSG
not depending on i.
Many studies report only a portion of the available
allelotypes (Matsumoto et al. 1997; Utada et al. 2000),
excluding those tumors that show little or no loss in the
region under study. It is clear that the allelotypes for
such studies inflate the apparent rates of loss in both the
background and at the putative TSG. Thus, although
selective reporting may produce potentially biased po-
sition estimates, our implementation of the instability-
selection model protects against the most obvious bias
by requiring that a region show excess loss compared
with other markers on the same chromosome within the
same study. We have also devised a nonparametric
method (further described below) that uses all the sum-
mary data of loss across the markers, and the results
from this approach agree very closely with the likelihood
results.
For all of the above reasons, we examine the allelotype
data within each study in a likelihood model for evidence
that . At a given position x, we compute the LODq 1 di i
function for study i (in a manner familiar from linkage
analysis) as
max L(data ; x,q ,d ,l )i i i i
q ,d ,li i iLOD (x)p logi 10 [ ]max L (data ; d ,l )H i i i0
d ,li i
or if in the numerator. The numer-ˆˆLOD (x)p 0 q ! di i i
ator profiles over qi, di, and li to evaluate at each position
x the relative evidence for the parameter of interest x*,
whereas the denominator does not depend on x. Max-
imizing over the parameters is relatively straightforward
to perform numerically, and published S-Plus scripts
(Newton and Lee 2000) can be used for a single study
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on one chromosome. However, we have found the soft-
ware to converge too slowly to be practical for our pur-
poses, and we have developed S-Plus functions that ap-
pear to converge more reliably and to evaluate the
likelihood much faster (∼50–100 times). For a fixed x
at an informative marker, the likelihood ratio is of a
regular nested form (Cox and Hinkley 1974), and, under
the null hypothesis, has a half-mass2 log (10)LOD (x)e i
at 0 (because of the constraint ) and half-massq  di i
approximately distributed as . This approximation is2x1
the basis for approximate pointwise P values (i.e., at a
fixed position x) and is somewhat conservative in inter-
vals between markers.
Results from Multiple Studies
Evaluating the evidence for many studies on a single
chromosome involves a simple extension of the above
approach, applied to the M studies on the current chro-
mosome. Denoting the vectors of parameters dp
and , the global null(d ,d , … ,d ) qp (q ,q , … ,q )1 2 M 1 2 M
hypothesis is that , versus the alternative that atdp q
least one . Thus, a locus exhibiting excess loss inq 1 di i
any of the studies is a TSG.
The resultant log-likelihood ratio is
max L(data; x,q,d,l)
q,d,lLOD(x)p log10 [ ]max L (data; d,l)H0
d,l
M
max  L(data ; x,q ,d ,l )i i i i
ip1q,d,lp log M10[ ]max  L (data ; d ,l )H i i i0
ip1d,l
p LOD (x) . i
i
At a fixed informative marker x, the distributional ap-
proximation for each LODi gives the null approximation
for LOD as proportional to a mixture of x2 distributions
with Y df, where Y is randomly drawn from Binomial
(M, 1/2) and under the assumption of a point mass at
0 when . The approximation is conservative, sinceYp 0
the LOD tends to be less extreme in genomic regions
covered by few markers. Note that estimating such a
large number of parameters can exact a heavy price in
statistical power; however, we were primarily concerned
with avoiding spurious “detection” of TSGs.
Display and Comparison
For a fixed x, the degrees of freedom in the null dis-
tribution of the LOD statistic depend on the number of
studies M, which varies by chromosome. Thus, the LOD
does not itself provide straightforward comparison of
the results on different chromosomes. We therefore find
it useful to use the distributional approximations for
LOD at fixed x to compute a pointwise P value at each
genomic position and display the results graphically as
. log P10
In understanding the overall biology of tumor sup-
pression, it is useful to be able to describe the relative
“importance” or strength of LOH in different genomic
regions. The LOD score and derived P values cannot serve
directly in this capacity, since they depend on the sample
size, whereas the estimated loss rate qi is study-specific
and should perhaps be considered in the context of dif-
fering background loss rates per chromosome. Although
this work is preliminary, we describe two initial ap-
proaches to the problem. The first approach is to use the
ratio between the maximum statistic per chro- log P10
mosome arm and the number of informative observations
as a rough indicator of the degree/importance of LOH (a
so-called LOH “strength index”). A more formal ap-
proach is to use the ratios , which have an interpre-q /di i
tation in terms of selection advantage in tumor growth
(Newton and Lee 2000). Heterogeneity and incomplete
chromosomal coverage of individual studies, however,
complicate the interpretation of these ratios. We adopted
a standard model from the meta-analysis literature (Der-
Simonian and Laird 1986), treating as randomlog (q /d )i i
effects drawn from a normal density with unknown over-
all chromosome-specific effect . The point esti-log (q/d)
mates were obtained at the point of maximumˆˆlog (q /d )i i
for each chromosome, and approximate SEs log P10
were obtained as 1/4 of the length of a 95% support
interval of the profile likelihood over the parameter space
of each . These SEs were used in standardlog (q /d )i i
weighted averages (Thompson 1998) of the tolog (q /d )i i
finally estimate .log (q/d)
As a final check of potential position bias, we also
employed a nonparametric positioning approach to the
summarized data for all tumors (see the “Results” section)
and found excellent agreement with the positions from
the likelihood approach. Although the details are some-
what cumbersome (see appendix B), the idea behind the
nonparametric procedure is quite simple. Within a study,
the overall loss proportions at each marker were used to
create a Z statistic for excess loss at each marker com-
pared with other markers on the same chromosome.
These scores were interpolated in the intervals between
markers, and then a weighted average across multiple
studies was computed.
Tests of Chromosomewide and Genomewide
Significance
In this setting, asymptotic theory has not been es-
tablished for excursions under H0 of the maximum
LOD across a chromosome. Newton and Lee (2000)
describe three approaches to the problem, using the
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Figure 2 Average LOH proportion per chromosome arm in 118 studies. The area of each circle is proportional to the total number of
informative marker observations on that arm across all studies. The global average LOH proportion of 0.318 is shown as a dotted line.
Poisson clumping heuristic, parametric bootstrapping,
or direct simulation of the LODi through use of the
maximum-likelihood estimates for di and li. The direct
simulation approach can be easily extended to a sum
of independent LODs and, for our purposes, was ini-
tially the most attractive. We applied our software to
the three sample data sets analyzed by the authors,
reproducing their LODs and parameter estimates. The
direct simulation P values under a dense-marker as-
sumption were slightly smaller but never less than half
of any of the P values obtained by Newton and Lee
(2000) by use of Poisson clumping or bootstrapping.
Thus, as a conservative approach, we obtained empir-
ical chromosomewide P values that were twice that
obtained from directly simulating 1,000 data sets for
all of the studies on each chromosome. The procedure
was computationally intensive, and we observed that
a Bonferroni procedure applied to the P values from
the grid of 200 LOD calculations per chromosome gave
very similar results and, for some chromosomes, was
even less conservative. For example, the median em-
pirical threshold for a chromosomewide significance
level of .05 was (range 2.73–4.16 log Pp 3.5210
across the chromosomes), compared with the Bonfer-
roni threshold . Here, the grid log (.05/200)p 3.6010
density was not entirely arbitrary, being chosen to min-
imize computation while ensuring that meaningful var-
iation in the LOD would not be overlooked.
Because the empirical procedure requires simplifying
assumptions and was apparently not much less conser-
vative than the Bonferroni thresholds, for simplicity, we
present results based on the latter. However, either pro-
cedure identified the same regions as attaining chro-
mosomewide significance, except for a minor conflict for
chromosome 4q (see the “Results” section). Although
we considered each chromosome worthy of independent
consideration in hypothesis testing, it also is helpful
to consider the corresponding genomewide threshold
. log [.05/(200# 23)]p 4.9610
Results
Average Loss
As an overall summary of LOH, we plotted the overall
average loss rate for each chromosome arm, using all
informative marker observations across the 118 studies
for which the summary data were available for all tumor
samples (fig. 2). For this analysis, we excluded the 33
articles that provided summary data on only a portion
of the samples, since these studies appeared to exclude
tumors showing little or no LOH. Although these latter
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Figure 3 A, Allelotype data on chromosome 1 from Bieche et al. (1999). Blackened circles represent LOH, unblackened circles represent
retention of heterozygosity, and dots represent noninformative observations. The X-axis of the allelotype data is aligned with the marker
positions. B, Resulting LOD scores.
studies are useful in the likelihood analyses below, they
offer potentially biased estimates of average loss. Be-
cause of the large number of studies represented, figure
2 provides a concise quantitative summary of loss rates
that have previously been available only as rough qual-
itative comparisons (Couch and Weber 1997). LOH pro-
portions are presented using symbols with area propor-
tional to the number of informative observations. Many
of the chromosomal arms with high loss rates also have
the greatest number of observations, because regions in-
itially reported to have high rates of loss were re-ex-
amined by subsequent investigators. The data support
reports that 17p and 16q have among the highest loss
rates (White et al. 1996; Shen et al. 2000). However, it
is notable that many chromosome arms described by
some as having high rates of loss (e.g., 1p and 11p)
(Lasko et al. 1991; Devilee and Cornelisse 1994) are not
exceptional compared with the overall average LOH
proportion of 0.318.
To illustrate the likelihood approach to mapping
TSGs, an example allelotype and resulting single-study
LOD is given in figure 3A and 3B, from the study by
Bieche et al. (1993) on chromosome 1. From the authors’
data, it is apparent that there is more evidence for excess
loss on 1p than 1q. However, the maximum LOD of
0.82 corresponds (by the simulation method described
above) to a chromosomewide P value of 0.65, and the
data are not extensive enough to support the authors’
conclusion that multiple distinct TSGs reside on 1p. The
data do appear to show distinct loss of entire arms or
interstitial deletions rather than a completely random
pattern of loss, a common feature of LOH data that is
explicitly incorporated in the model.
Computing the LOD scores for the individual studies
was straightforward, and the initial likelihood compu-
tation and the nonparametric procedure were performed
using the LDB map. Comparison of the relative positions
of the maximum LOD versus the maximum nonpara-
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Figure 4 Relative position estimates for the maximum-likeli-
hood statistic versus the maximum nonparametric statistics under the
LDB genetic map. The relative positions (expressed as a proportion
of the chromosome length) are presented for the 14 chromosomes with
significant chromosomewide LOD evidence. Subsequent likelihood
results differ somewhat, since they are based on physical genomic
position.
metric statistic (which used all summary data) revealed
good agreement for the 14 chromosomes showing sig-
nificant evidence of excess loss in the original LDB map
(fig. 4; ) and thus little evidence of substantialrp 0.98
position bias through the use of allelotypes. The greatest
disagreements were for chromosomes 8 and 18. Manual
review of the results suggested occasional difficulties in
the interpolation used in the nonparametric procedure.
This was especially pronounced for chromosome 8,
where the nonparametric procedure did give a large sec-
ondary peak near the maximum-likelihood position. We
adopted the likelihood procedure for all subsequent
computations, because of its greater interpretability.
Once the integrated physical marker map was created,
the likelihood computations were performed again, with
some examination necessary to detect convergence fail-
ures that appeared in four of the studies (observable as
sharp likelihood discontinuities or implausible LOD ev-
idence compared with the number of informative ob-
servations). For these studies, the LODs could be ap-
parently properly computed by changing the parameter
starting conditions or computing the LOD in reverse
(qter to pter), and removal of these studies did not ap-
preciably change the results. A study of chromosome 22
(Castells et al. 2000) repeatedly failed to converge, pos-
sibly because of small distances between markers show-
ing markedly different loss profiles (which can lead to
difficulty in estimation of l). Thus, in contrast to the
results for the other chromosomes, the results for chro-
mosome 22 are based on genetic distance, as judged by
the LDB, and then are linearly rescaled to correspond
to physical position. Again, removal of this study does
not affect our major conclusions.
Model-Based Evidence across the Genome
Figure 5 shows the evidence for preferential LOH
across the genome, using the common statistic , log P10
where P is the pointwise P value for the overall summed
LOD, as described in the “Material and Methods” sec-
tion. Several regions show striking evidence of preferential
loss, with in 7 regions and in 128 5P ! 10 P ! 10
regions. Regions with are significant at log P 1 4.9610
the .05 level in a genome scan. Chromosomes 7q, 16q,
13q, 17p, 8p, 21q, 3p, 18q, 2q, and 19p achieve this
threshold (table 2), and their significance was confirmed
using the empirical simulation-based approaches de-
scribed above. In addition, regions on 18p, 17p, 9p, 3p,
6q, and 1p exceeded the chromosomewide threshold
(we also list 4q because the chromo- log P 1 3.6010
somewide simulation P value was .046). The dashed lines
for chromosomes 8, 9, 10, 16, and 17 represent the
scores from the few studies that were known to log P10
have 120% noninvasive cases (almost exclusively DCIS).
There is not a clear correspondence between the LOD
evidence and the average loss rate on the chromosome
arm (fig. 2). For example, 7q shows strong evidence for
a TSG but an average loss rate of only 0.19, whereas
11q has relatively modest evidence for TSGs but an
above-average loss rate. It is important to note that our
approach searches for evidence of a single region of ex-
cess loss per chromosome, and a high background loss
rate or the contribution of multiple TSGs would make
it difficult to detect TSGs.
Support intervals of 3 LOD units (table 2) provide
some guidance for the regions likely to contain TSGs
and are intentionally conservative to account for uncer-
tainties in the draft genome assembly. Candidate TSGs
in the regions are listed on the basis of a review of the
literature and the primary LOH studies themselves. The
lists are not intended to be exhaustive, since the reso-
lution of LOH mapping is limited and numerous addi-
tional genes may have antiproliferative properties (e.g.,
Online Mendelian Inheritance in Man gives 419 entries
for “tumor suppressor,” although many of these are re-
dundant or have modest supporting evidence). The po-
sitions of a number of additional genes are also plotted
in figure 5. The plotted genes include the candidates in
table 2, genes listed by Couch and Weber (1997) as being
involved in hereditary syndromic breast cancers, and the
29 confirmed tumor suppressors discussed by Futreal et
al. (2001). We discuss in some detail the regions that
have been widely reported by others, which often cor-
respond to our regions showing greatest evidence. Other
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regions are discussed in less detail, with simple lists of
possible TSG candidates.
The greatest evidence of elevated LOH is at the fragile
7G region of chromosome 7q31.2 ( ) log Pp 17.7610
at 116.3 Mb, in the vicinity of CAV1 (MIM 601047)
(Osborne and Hamshere 2000; Fiucci et al. 2002) and
ST7 (MIM 600833), earlier reported to have suppressor
activity (Zenklusen et al. 2001). The role of ST7 has
been recently questioned (Brown et al. 2002; Dong and
Sidransky 2002), but our results nonetheless emphasize
the importance of a putative TSG in the immediate
vicinity.
Strong evidence ( ) was also ob- log Pp 11.6610
served on 16q24.3 at 91.9 Mb, one of two regions on
16q discussed by other researchers (Callen et al. 2002).
The region contains several promising candidates, in-
cluding the cadherins CDH13 (MIM 601364) (Toyooka
et al. 2001) and CDH15 (Kremmidiotis et al. 1998).
Previously, however, Kremmidiotis et al. (1998) had re-
ported that CDH13 appeared to be centromeric of the
LOH peak, which is consistent with our findings. Nearby
is the putative TSG CBFA2T3 (MIM 603870), with re-
duced expression in breast tissue (Kochetkova et al.
2002). CBFA2T3 was one of three genes reported as
showing wide variability in expression in breast cancer
cell lines (Powell et al. 2002) (the others were CYBA
[MIM 233690] and UniGene cluster Hs.7970). Also in
the region is FANCA (MIM 607139) of the Fanconi
anemia complementation group, thought to be associ-
ated with chromosomal instability and DNA repair
(Bogliolo et al. 2002).
The other major peak is at 16q22.1, near CDH1 (E-
cadherin [MIM 192090]) and CDH3 (MIM 114021),
with at 70.0 Mb (Cleton-Jansen et al. log Pp 9.6110
1994; Osborne and Hamshere 2000; Chalmers et al.
2001). The CDH1 protein has been shown to be lost/
reduced in breast cancer (Becker et al. 2002). The
FRA16B 33-bp expansion (Hsu and Wang 2002) was
directly placed using BLAT (UCSC Genome Browser,
available from the UCSC Genome Bioinformatics Home
Page) and appears to be centromeric of the peak. Finally,
a potential third region of loss is at 16q24.1, largely
because of a single noninvasive study (Chen et al. 1996).
Our LOD interval procedure suggests that this region
may be distinct from the other two, and, notably, the
LOD peak coincides almost exactly with WWOX/
FRA16D (MIM 605131) (Driouch et al. 1997; Bednarek
et al. 2001).
Chromosome 13q14 shows a broad region of elevated
loss (maximum at 39.1 Mb), unlike log Pp 11.0610
the other most significant regions, perhaps suggesting
the presence of multiple TSGs. The immediate interval
around the peak does not contain obvious candidates,
but BRCA2 (MIM 600185) (Kerangueven et al. 1995;
Forsti et al. 2001) lies in the broader region. In contrast,
the other major breast cancer susceptibility locus,
BRCA1 (17q), exhibits only minor evidence of prefer-
ential loss (fig. 3). Also in the broad region is AS3 (MIM
605333), reported to regulate androgen-induced prolif-
erative arrest in prostate cells (Geck et al. 1999). It has
been reported that D13S171, used as a marker of in-
stability in BRCA2, actually lies in AS3 (Geck et al.
2001), and we have confirmed this in recent genome
drafts. A second LOD peak on 13q near RB1 (MIM
180200) is of uncertain significance. The 13q21 region
reported as having evidence of linkage and somatic loss
by Kainu et al. (2000) ranges from 62.8 Mb to 75.9 Mb
and thus appears to be telomeric to our LOH evidence.
The results by Kainu et al. (2000) were confined to Scan-
dinavian families, and no linkage was found among
western European families with breast cancer in a recent
study (Thompson et al. 2002).
Chromosome 17p13.3 achieved similar significance
( at 0.8 Mb), almost at 17pter. The log Pp 10.4510
location coincides with ABR (MIM 600365), which may
be involved in chromosome rearrangements (Chen et al.
1998). HIC1 (MIM 603825) (Guerardel et al. 2001) is
nearby, as is DPH2L1 (or “OVCA1” [MIM 603527]),
which has a potential role in ovarian and breast cancer
(Phillips et al. 1996; Bruening et al. 1999; Salicioni et
al. 2000), but these genes may be centromeric of our
interval. Our findings are consistent with studies that
have found the greatest evidence for LOH on chromo-
some 17, telomeric to TP53 (MIM 191170) (Seitz et al.
2001). Further study is necessary to assess whether the
secondary peak at TP53 (fig. 5) is indeed distinct. In the
noninvasive studies, a smaller and broader peak on 17p
may include TP53 and MAP2K4 (MIM 601335) (Mur-
phy et al. 2002), but it is not clear that the peak is distinct
from that of invasive cancers.
8p21.3 has the next most striking evidence, with
at 19.7 Mb. N33 (MIM 601385) log Pp 9.4110
(MacGrogan et al. 1996) and PDGFRL (MIM 604584)
(Komiya et al. 1997) appear to be telomeric of the peak,
whereas LZTS1 (MIM 606551) (Cabeza-Arvelaiz et al.
2001) and FGF17 (Calvo et al. 2000) are possible can-
didates, although the latter may cause proliferation rather
than suppression. RHOBTB2 (or “DBC2” [MIM
607352]) (Hamaguchi et al. 2002) seems to be centromer-
ic of our peak. Hamaguchi et al. (2002) present functional
evidence for RHOBTB2 as a TSG, but deletion analysis
was performed for relatively few samples (six cell lines),
and further study of the region may be necessary.
Tumor necrosis superfamily members TNFRSF10A
(MIM 603611) and TNFRSF10B (MIM 603612) also lie
centromeric of our interval. It is intriguing that 8p21 is
another region implicated in nonsyndromic hereditary
breast cancer (Seitz et al. 1997; Adelaide et al. 1998).
The peak at 3p14.2 ( at 61.5 Mb) log Pp 7.9210
occurs very near the fragile site FRA3B, associated with
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Figure 5 Evidence for preferential LOH across the genome, expressed as derived from the LOD scores. Striking preferential log (P value)10
loss occurs in defined regions on several chromosomes. Gray horizontal lines show the chromosomewide significance threshold. The dashed
curves on certain chromosomes correspond to studies with a substantial proportion of noninvasive tumors. Chromosomes 12, 15, and 20 had
too few informative observations to fit the model, owing to purely technical aspects in maximizing the likelihood. Other chromosomes (in
particular 5 and 14, see table 1) had few observations, and the relative lack of evidence should be interpreted with caution. Centromeres are
indicated by black dots.
FHIT (MIM 601153) (Rassool et al. 1996; Le Beau et
al. 1998; Huiping et al. 2000). FHIT appears to be cen-
tromeric of the interval, a result somewhat consistent
with previous observations (Maitra et al. 2001), al-
though we do not exclude it as a candidate. MLH1
(MIM 120436) (Benachenhou et al. 1999) is clearly telo-
meric of the interval, and a minor peak occurs at
TGFBR2 (MIM 190182) (Lucke et al. 2001), with
at 32.8 Mb. log Pp 4.1110
Chromosome 21q11.1 has a peak of 9.00 log P10
at 16.5 Mb, near BTG3 (MIM 605674) (Matsuda et al.
2001) We do not find this or other candidates in the
region to be compelling. The peak at chromosome
18q21.2 ( ) is strikingly near DCC log Pp 7.3110
(MIM 120470) (Devilee et al. 1991; Ho et al. 1999),
whereas MADH4 (MIM 600993) (Hahn et al. 1996)
appears to be centromeric of the interval. The sharp
likelihood peak at 2q22.1 (based on few studies) coin-
cides with the hypothetical protein FLJ11857, which is
mentioned because the gene may have sequence simi-
larity with LRRC2 (MIM 607180) (Kiss et al. 2002),
itself occurring at a minor peak on 3p (fig. 4). LRP1B
(Liu et al. 2000) appears to be telomeric of the peak.
Similar evidence is on 19p13, near SAFB (MIM 602895)
(Oesterreich et al. 2001). The peak at 18p11.32 is near
EPB41L3 (MIM 605331) (Tran et al. 1999). Other, less
striking peaks include 9p21.3 (CDKN2A/p16 [MIM
600160] and IFNA4 [MIM 147564]) (Olopade et al.
1992; Milde-Langosch et al. 2001), 6q25.1 (ESR1 [MIM
133430] and IGF2R [MIM 147280]) (Murphy et al.
1996; Chen et al. 2002), 1p36.3 (SKI [MIM 164780]
and TP73 [MIM 601990]) (Shinagawa et al. 2001;
Stiewe and Putzer 2002), and 4q35.1 (FAT [MIM
600976]) (Mahoney et al. 1991).
Relative Strength of Elevated LOH
Figure 6A shows the relationship between the maxi-
mum on each chromosome arm and the total log P10
number of informative marker observations per arm. It
is apparent that 1p and 17q exhibit very modest evidence
for tumor suppressors compared with the extensive
study devoted to these regions. 7q achieves strong evi-
dence with relatively few observations, owing to a small
background loss rate, against which the excess loss in
7q31.2 is dramatic. The regions on 21q, 19p, and 2q
appear especially strong in light of comparatively few
observations. Figure 6B compares our rough strength
index (the ratio of Y vs. X coordinates from fig. 6A) to
the model-based estimate of described in thelog (q/d)
“Material and Methods” section. For either approach,
the regions on 19 and 21 appear to be the most striking.
There is reasonable agreement between the crude and
model-based approaches, with rank correlation coeffi-
cient 0.86.
Discussion
We have described the evidence for regions of elevated
LOH in breast cancer across the human genome, using
a likelihood-based approach designed to conservatively
handle the daunting issues of biological and technical
heterogeneity and incomplete marker coverage of indi-
vidual studies. We emphasize that our approach is de-
signed to look for evidence of preferential loss within a
chromosome and is not sensitive to elevated loss over
entire chromosomes, for which other approaches, such
as permutation procedures, may be appropriate (New-
ton et al. 1998). It will also be difficult to resolve multiple
nearby TSGs on the same chromosome without more
fine-scale coverage, although regions such as 16q22 and
16q24 appear to be clearly discernible. LOH analysis
cannot discern amplification/increases in DNA copy
number, and newer technologies of comparative genomic
hybridization (CGH), in concert with gene expression
analysis, may help identify regions involved in carci-
nogenesis (Pollack et al. 2002). While embracing such
technologies, it is also important to learn as much as
possible from existing data, and we have attempted to
perform meaningful inference on data collected over 12
years from numerous investigators. In a summary of the
difficulties of performing LOH analysis to map TSGs,
Devilee et al. (2001) concluded that finding TSGs might
require “brute force” approaches, presumably involving
analysis of many tumors. Our pooled analysis represents
one such approach. We find the difficulty in performing
LOH analysis in heterogeneous cancers to be reminiscent
of complex-trait linkage analysis, in which the identifi-
cation of the involved genes has proven more difficult
than hoped (Sham 2001). Similarly, the focus for breast
cancer LOH analysis should perhaps shift from imme-
diately identifying the supposed TSG to clearly estab-
lishing that excess LOH indeed exists in the region. In
any case, identifying a unique TSG may be difficult, even
in a region of proven excess loss, as is exemplified by
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Table 2
Regions of Elevated LOH, Listed in Descending Order of Evidence
Chromosome  log P10 Chromosomewide P
Position
(Mb)
3-LOD
Support
Interval
(Mb)
Candidate TSG(s)
(Position in Mb)
7q31.2 (FRA7G) 17.76 !.0001 116.3 115.7–119.0 TES (116.2), CAV1 (116.5), ST7
(MET region) (117.0)
16q24.3 11.66 !.0001 91.9 90.3–94.3 CDH13 (88.5), CBFA2T3 (92.5),
CDH15 (92.7), FANCA (93.2)
13q14.11 11.06 !.0001 39.1 38.8–42.1 BRCA2 (38.2), AS3 (38.5)
17p13.3 10.45 !.0001 .8 0–1.5 ABR (.8), OVCA1 (1.7), HIC1
(1.7)
16q22.1 (FRA16B) 9.61 !.0001 70.0 69.4–72.2 CDH3 (71.3), CDH1 (71.5)
8p21.3 9.41 !.0001 19.7 18.5–23.0 N33 (15.6), PDGFRL (17.8),
LZTS1 (18.6), FGF17 (20.4),
DBC2 (23.2)
21q11.1 9.00 !.0001 16.5 15.5–18.8 BTG3 (15.6)
3p14.2 (FRA3B) 7.92 !.0001 61.5 59.3–63.6 FHIT (63.5)
18q21.2 7.31 !.0001 53.2 51.7–54.8 DPC4 (51.1), DCC (53.3)
2q22.1 7.29 !.0001 136.3 134.5–137.7 FLJ11857 (135.5), LRP1B (138.5)
19p13.3 7.29 !.0001 6.2 4.6–6.9 SAFB (7.6)
16q24.1 (noninvasive, FRA16D) 5.66 .0004 83.0 72.9–89.8 WWOX (83.9)
18p11.32 4.86 .003 1.9 0–3.0 DAL1/EPBB41L3 (5.8)
17p13.2 (noninvasive) 4.81 .003 4.6 0–22.8 TP53 (8.0), MAP2K4 (13.6)
9p21.3 4.58 .005 26.6 26.2–27.5 CDKN2A/p16 (23.8), IFNA4 (24.5)
3p24.1 4.11 .016 32.8 22.1–40.4 TGFBR2 (32.6)
6q25.1 3.92 .024 156.9 151.8–170.3 ESR1 (159.3), IGF2R (167.3)
1p36.3 3.77 .034 1.3 0–10.5 SKI (1.5), TP73 (3.5)
4q35.1 3.59 .052 185.6 182.9–189.2 FAT (187.6)
the current controversy surrounding ST7 as a putative
TSG at 7q31 (Zenklusen et al. 2001; Brown et al. 2002;
Dong and Sidransky 2002).
Despite these challenges, our results are surprisingly
clear in their support of excess LOH in several regions,
with very modest evidence in other regions. An example
of the latter is 11q, although certain subgroups may
show excess loss (Gentile et al. 2001). The data suggest
that regions on chromosomes 19 and 21 are deserving
of further investigation, whereas no conclusions can be
made for other regions, including the entire chromo-
somes 12, 15, and 20. Some features are immediately
apparent in figure 5 that have only recently been noticed
by other researchers—for example, that TP53 shows
only a minor peak and that the greatest evidence for a
TSG is further telomeric on 17p (Seitz et al. 2001). The
evidence for excess LOH at BRCA1 is not compelling,
whereas, at/near BRCA2, the evidence is strong. We
emphasize that the lack of excess LOH in these (mostly
sporadic) breast cancers does not preclude LOH as a
feature in hereditary breast cancer (Bell et al. 2002).
The distinct peaks on 16q are also heartening, since
recent progress has been made in dissecting these regions
of LOH (Callen et al. 2002). The coincidental location
of excess loss on 8p21 with a putative hereditary breast
cancer gene (Seitz et al. 1997) may support the possi-
bility of combined linkage/LOH studies to identify the
putative TSG.
In general, genes causing inherited rare syndromic
breast cancer susceptibility were not in regions of sub-
stantially elevated loss. We have described the compar-
ative lack of evidence at TP53 (Li-Fraumeni syndrome
[MIM 151623]; 17p13), and the peaks at PTEN (MIM
601728) (Cowden disease [MIM 158350]; 10q23) and
ATM (MIM 208900) (ataxia-telangiectasia; 11q22) are
also relatively modest. MLH1 (hereditary nonpolyposis
colorectal cancer [MIM 120436]; 3p21) shows elevated
loss but is telomeric to the high peak on 3p14, and
STK11 (MIM 602216) (Peutz-Jeghers syndrome [MIM
175200]) is telomeric to the region of elevated loss on
19p13.
We also examined the location of genes described in
a recent review by Kolodner et al. (2002) as mutated
in human cancer susceptibility syndromes and having
yeast homologs involved in cell checkpoints and ge-
nome stability. Of eight such genes, only WRN (MIM
604611) (Werner syndrome [MIM 277700]; 8p12) re-
sides in a region of substantial preferential loss and is
clearly centromeric to the 8p21 peak. We did not find
compelling homologs of other yeast checkpoint genes,
but several human homologs reside on chromosome 15,
which has few LOH data. Although yeast is an impor-
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Figure 6 The degree of preferential loss varies on the genome.
A, Maximum observed on each chromosome arm versus log P10
informative observations for that arm (arms with and log P ! 2.010
!500 informative observations are not labeled). The horizontal lines
show the chromosomewide significance threshold. Despite extensive
study, arms such as 17q, 1p, 6q, 11p, and 11q exhibit modest evidence
for preferential loss. Chromosome arms 21q, 19p, and 2q show strik-
ing evidence based on relatively few observations and deserve further
study. B, For each chromosome, the estimated effect according to the
instability selection model accounting for population heterogeneity
versus a simple “strength index,” defined as /(infor-max ( log P)10
mative observations) for the chromosome (both axes on natural log
scale). Several chromosomes (5, 12, 15, and 20) had too few obser-
vations for reliable estimates.
tant model for investigations of genome stability and
spontaneous rearrangements, the connection with LOH
in human breast cancer remains uncertain.
One surprising finding is the concordance of common
fragile sites with regions of excess LOH. Of five fragile
sites described in a recent review (Huebner and Croce
2001) as possibly related to cancer, three (FRA3B,
FRA7G, and FRA16D) are at or very near peaks in our
LOD score. Of the remaining two, FRA7H may show
a bystander effect of elevated LOH due to loss at
FRA7G, whereas FRAXB has been implicated mostly
in cell lines (Smith et al. 1998; Arlt et al. 2002). In this
context, the peak at ABR (active breakpoint cluster-
related) at 17pter is intriguing. The results are not en-
tirely unexpected, since roughly coincidental positions
of fragile sites and translocations have been suggested
(Yunis and Soreng 1984). However, we have not found
much concordance of excess LOH with more recent
summaries of chromosomal rearrangements in neopla-
sia (Mitelman 2000), and the proliferation of reported
regions of breast cancer LOH over the years has made
it difficult to sift through the evidence in a systematic
manner.
A possible technical difficulty is that current ap-
proaches for detecting LOH can be sensitive to other
sources of allelic imbalance, including amplification
(Devilee et al. 2001). Shen et al. (2000) present argu-
ments that, for their extensive data, this did not appear
to be a concern. We also compared our results with
those of Richard et al. (2000), who performed CGH on
105 breast tumors. The CGH results are at lower res-
olution, but we found broad agreement in that either
the ductal or lobular carcinomas showed evidence of
loss in the regions we identified. An exception is 19p,
which they find to be a region of amplification (Richard
et al. 2000). Several other regions of loss highlighted in
the CGH data are not reflected in our results, perhaps
reflecting elevated but nonspecific broad regions of
LOH.
In contrast to our compiled LOH data, catalogs of
chromosomal aberrations, such as the Mitelman data-
base (Mitelman Database of Chromosome Aberrations
in Cancer Web site), may describe multiple cytogenetic
abnormalities per patient/tumor, as do genomewide ap-
proaches such as CGH (Kallioniemi et al. 1992). These
techniques enable the exploration of correlated patterns
of losses and gains, potentially giving clues to the time-
line or causality of aberration events (Desper et al.
1999). The resolution of LOH-based mapping (or array-
based CGH), however, is typically much greater and
may enable such causal exploration if entire genome
scans are performed for all tumors in a study.
One sobering conclusion from the present study is that
a single large LOH study could have provided much of
the same information, provided sufficient tumor material
was available. Relatively few markers were examined in
most of the compiled studies, so that the 15,000 tumors
resulted in just 83,000 informative marker observations.
Thus, a single study involving 415 tumors on a standard
400-marker panel would be crudely equivalent to our
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entire database (assuming that only half of the marker
observations were informative). Such a study would
likely have inferior resolution in currently well-studied
regions (e.g., 17p) but would offer important new in-
formation in numerous other regions of the genome and
enable the correlation of loss events across the genome.
Moreover, many of the technical issues of heterogeneity
and differing LOH criteria would not arise in the analysis
of a single large study. The ambitious effort by Shen et
al. (2000) is a step in this direction; they examined 100
laser-capture microdissected tumor samples at 400 mark-
ers (the article did not contain primary data and so did
not meet our inclusion criteria).
In our analysis, we have attempted to extract simple
conclusions from disparate and heterogeneous data. The
same approach could be used to analyze data for nu-
merous other cancers for which considerable LOH data
have been published, including cancers of the lung, kid-
ney, prostate, colon, and skin. Continuing improvements
in the draft human genome may enable refinements in
TSG support intervals (as in table 2) to perhaps 1–2 Mb
and may help resolve some controversies over the sup-
porting evidence for candidate TSGs. For CGH array
data, an obvious further extension of the likelihood
model would include regions of amplification in a similar
manner as regions of loss. In addition, the combined
analysis of gene expression and changes in DNA copy
number (Pollack et al. 2002) may provide additional
clues to identify genes involved in carcinogenesis.
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Appendix A
The Instability-Selection Likelihood
For a single study and tumor j, we use to indicate the loss of heterozygosity at position x, orS (x)j
0, no loss at x
S (x)p .j {1, loss at x
For ordered positions and prior to selection, a consequence of the sporadic random loss model of∗x ! x ! x1 2
chromosomal segments is that is a Markov process, with transition probabilities at the lociS (x)j
lFx x F lFx x F2 1 2 1[ ] [ ]Pr S (x )p 1FS (x )p 0pd(1 e ), Pr S (x )p 0FS (x )p 1p(1 d)(1 e ) .j 2 j 1 j 2 j 1
We use to denote a realized loss value at the kth marker ( ) of tumor j, and the likelihood for thes (x ) kp 1, … ,Kj k
entire process is
no.of tumors
∗[ ]L(x,d,q,l)p Pr s (x ) ,s (x ), … ,s (x )Fxp x ,d,q,l . j 1 j 2 j K
jp1
Even after selection has occurred, computing the likelihood within each tumor is straightforward by the Markov
process after conditioning on the loss event at x*, which has marginal probability . Positions∗Pr [S (x )p 1]p qj
to the left of x* follow an identically distributed process in the opposite direction. Noninformative marker obser-
vations are considered missing at random and involve simply skipping the missing marker in computing the likelihood
contribution of an individual tumor. Further details are available from Newton and Lee (2000).
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Appendix B
A Nonparametric Procedure for Identifying Preferential
Loss
In examining the data from numerous studies, it is
helpful to have a procedure to scan for evidence of pref-
erential loss without the need to rely on a specific model.
We devised such an approach through use of the loss
proportions (loss divided by total informative observa-
tions) at each marker compared with other markers on
the chromosome in the same study. For each marker, the
simple statistic for comparing binomial proportions can
be computed as
p  p1 2zp
p (1p ) p (1p )1 1 2 2 n n1 2
where p1 is the observed loss proportion at the current
marker, p2 is the loss proportion at all remaining markers
on the chromosome in the study, and n1 and n2 are the
respective numbers of informative observations. Under
the null hypothesis that the true LOH does not vary on
the chromosome, and if the markers are uncorrelated,
at each marker. Note that, in practice, the
.
z ∼ N(0,1)
statistic is conservative, because positive correlation in
loss (induced by deletions of chromosome segments) re-
sults in overestimation of in the denomi-Var (p  p )1 2
nator. We further devised a means for summarizing the
evidence at each position across all studies. Although
the details (below) are somewhat cumbersome, the key
features are that the statistic is computed over the range
of markers within each study, and a weighted sum over
multiple studies provides a single summary. A conser-
vative test for chromosomewide significance can be ap-
plied, using random permutations of data within each
study.
We use Ri to denote the range of markers in study i,
and the Z statistic defined above for each marker is
linearly interpolated across successive markers to create
a statistic for each position , withZ (x) x  R Z (x){i i i
elsewhere. A summary statistic across the studies is0
computed as , where Wi is aT(x)p  W(x)Z (x)I 1i i [Z (x) 0]i i
weighting function and I[A] denotes the indicator for
event A. The weights are based on bi, the mean number
of informative tumors per marker in study i, and are
scaled as . The use of the indi-W(x)p b / b I′′ ′i i i [xR ]i i
cator ensures that T cannot be negative and reflects that
we do not consider from study i to be mean-Z (x) ! 0i
ingful countervailing evidence against preferential loss
in, say, another study at the same position. A pointwise
P value is easily obtained numerically using the half-
normal approximation for each of the components in
the sum. The location of the minimum pointwise P val-
ues were used to obtain TSG location estimates on each
chromosome.
Although not necessary for our study, a test of chro-
mosomewide significance for T can be performed by
permuting, for each study and each chromosome, the
loss observations across all informative marker obser-
vations on that chromosome and computing formax (T)
each permutation. The proportion of the empirical
values exceeding the observed value form anmax (T)
empirical P value. This P value is conservative (some-
times highly so), since, even in the absence of a tumor
suppressor, deletions of interstitial regions or entire arms
produce positive correlation in loss events. The per-
mutation samples eliminate this correlation, producing
higher excursions of the T statistic.
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